177 related articles for article (PubMed ID: 33032968)
1. A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy.
Fankhauser CD; Tran B; Pedregal M; Ruiz-Morales JM; Gonzalez-Billalabeitia E; Patrikidou A; Amir E; Seidel C; Bokemeyer C; Hermanns T; Rumyantsev A; Tryakin A; Brito M; Fléchon A; Kwan EM; Cheng T; Castellano D; Del Muro XG; Hamid AA; Ottaviano M; Palmieri G; Kitson R; Reid A; Heng DYC; Bedard PL; Sweeney CJ; Connors JM
Eur Urol Focus; 2021 Sep; 7(5):1130-1136. PubMed ID: 33032968
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolic events in patients undergoing craniotomy for tumor resection: incidence, predictors, and review of literature.
Rinaldo L; Brown DA; Bhargav AG; Rusheen AE; Naylor RM; Gilder HE; Monie DD; Youssef SJ; Parney IF
J Neurosurg; 2019 Jan; 132(1):10-21. PubMed ID: 30611138
[TBL] [Abstract][Full Text] [Related]
3. The timing of venous thromboembolic events after spine surgery: a single-center experience with 6869 consecutive patients.
Cloney MB; Hopkins B; Dhillon ES; Dahdaleh NS
J Neurosurg Spine; 2018 Jan; 28(1):88-95. PubMed ID: 29125431
[TBL] [Abstract][Full Text] [Related]
4. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3).
Tran B; Ruiz-Morales JM; Gonzalez-Billalabeitia E; Patrikidou A; Amir E; Seidel C; Bokemeyer C; Fankhauser C; Hermanns T; Rumyantsev A; Tryakin A; Brito M; Fléchon A; Kwan EM; Cheng T; Castellano D; Garcia Del Muro X; Hamid AA; Ottaviano M; Palmieri G; Kitson R; Reid A; Heng DYC; Bedard PL
Cancer Med; 2020 Jan; 9(1):116-124. PubMed ID: 31715650
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparin prophylaxis is not associated with decreased incidence of venous thromboembolism in testicular germ cell tumor patients receiving chemotherapy.
Hapakova N; Chovanec M; Rejlekova K; Kalavska K; Obertova J; Palacka P; De Angelis V; Sycova-Mila Z; Mardiak J; Mego M
Neoplasma; 2022 Mar; 69(2):456-463. PubMed ID: 35068164
[TBL] [Abstract][Full Text] [Related]
6. Primary Thromboprophylaxis and the Risk of Venous Thromboembolic Events in Patients With Testicular Germ Cell Tumors Treated With Cisplatinum-Based Chemotherapy.
Terbuch A; Walser G; Stotz M; Gerger A; Posch F; Bauernhofer T
Clin Genitourin Cancer; 2023 Feb; 21(1):24-31. PubMed ID: 36400695
[TBL] [Abstract][Full Text] [Related]
7. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.
Gizzi M; Oberic L; Massard C; Poterie A; Le Teuff G; Loriot Y; Albiges L; Baciarello G; Michels J; Bossi A; Blanchard P; Escudier B; Fizazi K
Eur J Cancer; 2016 Dec; 69():151-157. PubMed ID: 27821318
[TBL] [Abstract][Full Text] [Related]
8. Timing of Prophylactic Anticoagulation and Its Effect on Thromboembolic Events After Surgery for Metastatic Tumors of the Spine.
De la Garza Ramos R; Longo M; Gelfand Y; Echt M; Kinon MD; Yassari R
Spine (Phila Pa 1976); 2019 Jun; 44(11):E650-E655. PubMed ID: 30475345
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study.
Haugnes HS; Negaard HF; Jensvoll H; Wilsgaard T; Tandstad T; Solberg A
Eur Urol Open Sci; 2021 Oct; 32():19-27. PubMed ID: 34667955
[TBL] [Abstract][Full Text] [Related]
10. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer.
Hachey KJ; Hewes PD; Porter LP; Ridyard DG; Rosenkranz P; McAneny D; Fernando HC; Litle VR
J Thorac Cardiovasc Surg; 2016 Jan; 151(1):37-44.e1. PubMed ID: 26386868
[TBL] [Abstract][Full Text] [Related]
11. Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism.
Kahn SR; Morrison DR; Cohen JM; Emed J; Tagalakis V; Roussin A; Geerts W
Cochrane Database Syst Rev; 2013 Jul; (7):CD008201. PubMed ID: 23861035
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolic events in glioblastoma patients: An epidemiological study.
Eisele A; Seystahl K; Rushing EJ; Roth P; Le Rhun E; Weller M; Gramatzki D
Eur J Neurol; 2022 Aug; 29(8):2386-2397. PubMed ID: 35545894
[TBL] [Abstract][Full Text] [Related]
13. Incidence and Risk Model of Venous Thromboembolism in Patients with Aneurysmal Subarachnoid Hemorrhage.
Pan J; Bonow RH; Temkin N; Robinson EF; Sekhar LN; Levitt MR; Lele AV
World Neurosurg; 2023 Apr; 172():e418-e427. PubMed ID: 36657716
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients.
Gritsiouk Y; Hegsted DA; Schlesinger P; Gardiner SK; Gubler KD
Am J Surg; 2014 May; 207(5):648-51; discussion 651-2. PubMed ID: 24560359
[TBL] [Abstract][Full Text] [Related]
15. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021.
Fankhauser CD; Oldenburg J; Albers P; Algaba F; Bokemeyer C; Boormans JL; Fischer S; Fizazi K; Gremmels H; Mayor de Castro J; Janisch F; Muilwijk T; Leão R; Nicol D; Nicolai N; Tandstad T; Pilar Laguna M
Eur Urol; 2021 Jul; 80(1):4-6. PubMed ID: 33722419
[TBL] [Abstract][Full Text] [Related]
16. A narrative review on the epidemiology, prevention, and treatment of venous thromboembolic events in the context of chronic venous disease.
Kemp MT; Obi AT; Henke PK; Wakefield TW
J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1557-1567. PubMed ID: 33866055
[TBL] [Abstract][Full Text] [Related]
17. A Cohort Study of Incidences and Risk Factors for Thromboembolic Events in Patients with Idiopathic Membranous Nephropathy.
Zou PM; Li H; Cai JF; Chen ZJ; Li C; Xu P; Li MX; Chen LM; Li XM; Li XW
Chin Med Sci J; 2018 Jun; 33(2):91-99. PubMed ID: 29976278
[TBL] [Abstract][Full Text] [Related]
18. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.
Wille K; Sadjadian P; Becker T; Kolatzki V; Horstmann A; Fuchs C; Griesshammer M
Ann Hematol; 2019 Jan; 98(1):93-100. PubMed ID: 30155552
[TBL] [Abstract][Full Text] [Related]
19. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
20. Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
Senay A; Trottier M; Delisle J; Banica A; Benoit B; Laflamme GY; Malo M; Nguyen H; Ranger P; Fernandes JC
Vasc Health Risk Manag; 2018; 14():81-89. PubMed ID: 29780248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
